Figure 23 is titled “Mean change from baseline in CAPS for SSRIs compared with placebo.” The figure displays a forest plot reporting the standardized mean difference in CAPS stratified by citalopram compared with placebo, fluoxetine compared with placebo, paroxetine compared with placebo, and setraline compared with placebo. Data for Figure 23 are presented in Appendix F. This figure is described further in the “PTSD symptom reduction” section as follows: “Our meta-analyses found fluoxetine, paroxetine, and sertraline to improve PTSD symptoms, as measured by improvement in CAPS, more than placebo. We found no statistically significant difference between citalopram and placebo, and results trended in favor of placebo (1 trial). Magnitude of benefit ranged from a difference of −4.9 for sertraline to −12.6 for paroxetine compared with placebo. The meta-analyses for change in CAPS did not have significant statistical heterogeneity for any of the individual medications compared with placebo (I2=0% for each).”

Figure 23Mean change from baseline in CAPS for SSRIs compared with placebo

Note: Timing of outcome assessment: 10 weeks (Tucker, 2003;155 Zohar, 2002170), 12 weeks (Martenyi, 2007;161 Martenyi, 2002;159 Marshall, 2001;163 Tucker, 2001;134 Brady, 2005;166 Brady, 2000;165 Davidson, 2001;167 Friedman, 2007;168 Davidson, 2006133), 8 weeks (van der Kolk, 2007),113 5 weeks (van der Kolk, 1994).162

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.